SCHEMBL16748428

SCHEMBL16748428

CCc1nc2c(F)cc(F)cc2n1-c1nc(N)nc(Nc2ccc(Br)cc2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGPAT2 O15120 4/20 0.40
EGFR P00533 2/20 0.36
BMI1 P35226 3/20 0.35
CYBB P04839 1/20 0.35
NOX5 Q96PH1 1/20 0.35
NOX3 Q9HBY0 1/20 0.35
NOX4 Q9NPH5 1/20 0.35
NOX1 Q9Y5S8 1/20 0.35
ALDH1A1 P00352 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
BLM P54132 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
KDM4E B2RXH2 1/20 0.34
NPC1 O15118 3/20 0.34
RAB9A P51151 3/20 0.34
MAPT P10636 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
PABPC1 P11940 1/20 0.34
JAK2 O60674 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16748593 0.92 CYBB (0.42) AGPAT2BMI1CYBBNOX5NOX3
SCHEMBL16748421 0.90 AGPAT2 (0.41) AGPAT2EGFRBMI1CYBBNOX5
SCHEMBL16748436 0.89 AGPAT2 (0.42) AGPAT2EGFRBMI1CYBBNOX5
SCHEMBL16740864 0.89 BMI1 (0.48) AGPAT2BMI1CYBBNOX5NOX3
SCHEMBL16748597 0.89 MAPT (0.44) BMI1ALDH1A1TDP1SMN1; SMN2KDM4E
SCHEMBL16740729 0.87 AGPAT2 (0.39) AGPAT2EGFRBMI1CYBBNOX5
SCHEMBL16748425 0.87 MAPK1 (0.36) BMI1CYBBNOX5NOX3NOX4
SCHEMBL16740783 0.86 BMI1 (0.50) BMI1ALDH1A1KDM4ENPC1RAB9A
SCHEMBL16740728 0.85 BMI1 (0.50) AGPAT2EGFRBMI1CYBBNOX5
SCHEMBL16740830 0.83 BMI1 (0.42) AGPAT2EGFRBMI1CYBBNOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US claimed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US claimed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B AGPAT2 3973/4885EGFR 3189/4885BMI1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.